Comparing neoadjuvant therapy followed by local excision to total mesorectal excision in the treatment of early stage rectal cancer: a systematic review and meta-analysis of randomised clinical trials
International Journal of Colorectal Disease · 2023
DOI: 10.1007/s00384-023-04558-8 ↗Kurz gefasst
Metaanalyse in der Zeitschrift International Journal of Colorectal Disease, 2023. Verfasst von Paul Lynch und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Colorectal Surgery, St. Vincent's University Hospital, Elm Park, Dublin 4, Ireland. Hauptthemen laut MEDLINE: Rectum, Rectal Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 63 Literaturangaben.
Abstract (Originalsprache)
INTRODUCTION: Total mesorectal excision (TME) is the standard-of-care in early, clinical stage (cT2-3 N0 M0) rectal cancer. Local excision (LE) may be an alternative after adequate response to neoadjuvant therapy (NAT), with either long-course chemoradiotherapy (nCRT) or short-course radiotherapy (SCRT), as a means of preserving the rectum and potentially obviating the morbidity of TME. METHODS: A systematic review was performed according to PRISMA guidelines for studies that randomly assigned patients with cT2-3 N0 M0 rectal cancer to either NAT + LE or TME that reported radiologic, oncologic, surgical, and morbidity outcomes. RESULTS: A total of 4 RCTs comprise 462 patients (232 patients receiving NAT + LE; nCRT n = 205; SCRT n = 27) and 230 undergoing TME, respectively. NAT compliance was 98.86%. The rate of early completion TME in the NAT + LE group was 22.3%, while the proportion of patients achieving durable organ preservation was 75.4% at mean follow-up of 5.6 years. There was no difference in disease-free survival (DFS) (HR [hazard ratio] 1.19; 95% CI 0.95, 1.49; p = 0.13) or overall survival (OS) (HR 0.94; 95% CI 0.72, 1.23; p = 0.63]) according to the assigned treatment arm. The local recurrence rate (LRR) (HR 1.22; 95% CI 0.5-3.02; p = 0.66) and distant metastases (HR 0.92; 95% CI 0.45, 1.90; p = 0.82) were also comparable between the groups. There was a significant reduction in major (OR 0.45; 95% CI 0.21, 0.95; p = 0.04) and minor morbidity (OR 0.45; 95% CI 0.24, 0.85; p = 0.01) for patients undergoing NAT + LE. Overall stoma formation was decreased in the NAT + LE group (OR 0.03; 95% CI 0.0, 0.23; p ≤ 0.00001). CONCLUSION: NAT + LE reduces adverse effects of TME, without any compromise in oncological outcomes, and the potential for an organ preserving strategy should be discussed with patients with T2-3N0 rectal cancers prior to treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Colorectal Surgery, St. Vincent's University Hospital, Elm Park, Dublin 4, Ireland.
- Department of Colorectal Surgery, St. Vincent's University Hospital, Elm Park, Dublin 4, Ireland. eannaryan@rcsi.com.
Zitieren
APA
Lynch, P., Ryan, O. K., Donnelly, M., Ryan, É. J., Davey, M. G., Reynolds, I. S., Creavin, B., Hanly, A., Kennelly, R., Martin, S. T., & Winter, D. C. (2023). Comparing neoadjuvant therapy followed by local excision to total mesorectal excision in the treatment of early stage rectal cancer: a systematic review and meta-analysis of randomised clinical trials. International Journal of Colorectal Disease. https://doi.org/10.1007/s00384-023-04558-8
Vancouver
Lynch P, Ryan OK, Donnelly M, Ryan ÉJ, Davey MG, Reynolds IS, et al. Comparing neoadjuvant therapy followed by local excision to total mesorectal excision in the treatment of early stage rectal cancer: a systematic review and meta-analysis of randomised clinical trials. International Journal of Colorectal Disease. 2023. doi:10.1007/s00384-023-04558-8
BibTeX
@article{Lynch2023,
author = {Lynch, Paul and Ryan, Odhrán K and Donnelly, Mark and Ryan, Éanna J and Davey, Matthew G and Reynolds, Ian S and Creavin, Ben and Hanly, Ann and Kennelly, Rory and Martin, Seán T and Winter, Des C},
title = {Comparing neoadjuvant therapy followed by local excision to total mesorectal excision in the treatment of early stage rectal cancer: a systematic review and meta-analysis of randomised clinical trials},
journal = {International Journal of Colorectal Disease},
year = {2023},
doi = {10.1007/s00384-023-04558-8}
}
EUVIMED